Phase I Study of Safety and Immunogenicity of an Escherichia coli-Derived Recombinant Protective Antigen (rPA) Vaccine to Prevent Anthrax in Adults by Brown, Bruce K. et al.
Phase I Study of Safety and Immunogenicity of an
Escherichia coli-Derived Recombinant Protective Antigen
(rPA) Vaccine to Prevent Anthrax in Adults
Bruce K. Brown
1, Josephine Cox
1, Anita Gillis
1, Thomas C. VanCott
1, Mary Marovich
2, Mark Milazzo
1,
Tanya Santelli Antonille
1, Lindsay Wieczorek
1, Kelly T. McKee Jr
3, Karen Metcalfe
3, Raburn M. Mallory
3,
Deborah Birx
2, Victoria R. Polonis
2, Merlin L. Robb
1*
1United States Military HIV Research Program, Henry M. Jackson Foundation, Rockville, Maryland, United States of America, 2United States Military HIV Research Program,
Walter Reed Army Institute of Research, Rockville, Maryland, United States of America, 3DynPort Vaccine Company LLC, Frederick, Maryland, United States of America
Abstract
Background: The fatal disease caused by Bacillus anthracis is preventable with a prophylactic vaccine. The currently
available anthrax vaccine requires a lengthy immunization schedule, and simpler and more immunogenic options for
protection against anthrax are a priority for development. In this report we describe a phase I clinical trial testing the safety
and immunogenicity of an anthrax vaccine using recombinant Escherichia coli-derived, B. anthracis protective antigen (rPA).
Methodology/Principal Findings: A total of 73 healthy adults ages 18–40 were enrolled and 67 received 2 injections
separated by 4 weeks of either buffered saline placebo, or rPA formulated with or without 704 mg/ml AlhydrogelH adjuvant
in increasing doses (5, 25, 50, 100 mg) of rPA. Participants were followed for one year and safety and immunologic data were
assessed. Tenderness and warmth were the most common post-injection site reactions. No serious adverse events related to
the vaccine were observed. The most robust humoral immune responses were observed in subjects receiving 50 mg of rPA
formulated with AlhydrogelH with a geometric mean concentration of anti-rPA IgG antibodies of 283 mg/ml and a toxin
neutralizing geometric 50% reciprocal geometric mean titer of 1061. The highest lymphoproliferative peak cellular response
(median Lymphocyte Stimulation Index of 29) was observed in the group receiving 25 mg AlhydrogelH-formulated rPA.
Conclusions/Significance: The vaccine was safe, well tolerated and stimulated a robust humoral and cellular response after
two doses.
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Introduction
Bacillus anthracis is a gram positive, facultative anaerobic, rod-
shaped bacterium that has the ability to form endospores. Due to
their durability, the endospores have the potential to be
weaponized and therefore pose a threat for use by terrorists
and/or adversary governments. B. anthracis produces a tripartite
toxin composed of: protective antigen (PA), edema factor (EF), and
lethal factor (LF). The binding of PA to the target cell initiates a
sequence of events that result in EF and LF accessing the cytosol of
the target cell, eventually culminating in cell death [1]. The bio-
terrorism attacks in 2001 involving spore-laden envelopes mailed
to individuals in the U.S. Capitol building and elsewhere have
reinforced the need for vaccination strategies to protect against
anthrax exposures.
The currently licensed anthrax vaccine in the U.S., Bio-
Thrax
TM (previously called anthrax vaccine adsorbed, or AVA),
protects against inhalation anthrax in monkeys and rabbits [2,3,4]
and a prior version of the vaccine conferred protection from
occupational exposure in humans [5]. Biothrax
TM is a cell-free
filtrate and while the components of the vaccine have not been
fully elucidated, the major immunogen in this vaccine is PA [6]. It
has been well documented in animal challenge studies that
antibodies against PA lead to protection from anthrax exposure
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13849[7]. The next generation of vaccines has focused on using rPA
expressed in prokaryotic systems such as B. anthracis and Escherichia
coli (E. coli) as the sole immunogen.
The primary immunization schedule for BioThrax
TM in
humans is time intensive, requiring up to 5 injections spaced over
an 18 month period [8]. Although determined to be safe by the
FDA [9] and more recently by the VAERS Working Group [10],
there is still controversy surrounding the safety profile of this
product. Specifically, local and systemic reactions to the vaccine
are reported to be more common and of longer duration
compared to other experimental rPA vaccines [11,12]. These
drawbacks, real or perceived, have stimulated a desire to develop
new vaccines to prevent anthrax. These new vaccines would likely
be available to U.S. defense forces, to emergency support
personnel, as well as to the general public, for protection from
potential bioweapon attacks.
Currently, there are two reports of B. anthracis expressed rPA
vaccines in humans [13,14]. Similar humoral responses to the rPA
vaccines were reported in both of these studies, despite differences
in the amount of adjuvant used and the number of vaccinations.
Herein, we report the results of a randomized phase I clinical trial
of an E. coli expressed rPA vaccine administered to humans. The
humoral responses we observed following administration of two
injections of the current rPA vaccine were found to be similar to
those previously reported [13,14]. In addition, we provide data
for the first time on the cellular immune response to rPA in
humans.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Objectives
This study aimed to assess the safety and immunogenicity of an
anthrax vaccine in which a recombinant Escherichia coli-derived, B.
anthracis protective antigen is the principal antigenic component.
Participants and Randomization
The study enrolled 73 healthy adults age 18 to 40 years who
were anthrax vaccine naı ¨ve. If any participants were unable to
complete the vaccine schedule for any reason, they were replaced
within the study recruitment time period. The inclusion and
exclusion criteria are described in detail in the included trial
protocol. Briefly, individuals were required to be between 18 and
40 years of age, and in good health. Individuals who had chronic
medical or psychiatric illness, required immune modulators,
reported drug or alcohol abuse or were unable to meet all
required protocol visits were excluded. The first 12 participants
received 5 mg of active vaccine with or without adjuvant under
open label (i.e., not blinded) to test initial safety; the remaining
study subjects were blinded to receipt of vaccine or placebo. For
the blinded portion of the study, the study statistician prepared a
randomization list using the RANUNI function in SAS Version 8
(SAS Institute, Cary, NC USA); only the study pharmacist and the
statistician had access to this randomization list, and study
personnel were unblinded only after study completion. The study
plan is diagramed in a CONSORT flowchart (Figure 1). Safety
data was analyzed and reported on every subject (73 total) at every
available time point immediately after initial injection. These
include immediate reactions and at 48–72 hours and 2 weeks post
each injection. Longer term safety and immune response data was
collected at visits 6, 10, 16, 26, 36, and 52 weeks after the initial
injection. Serious adverse events were solicited at all time points
through the 52 week visit. All adverse and serious adverse events
Figure 1. CONSORT flowchart.
doi:10.1371/journal.pone.0013849.g001
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associated with vaccines, as recommended by the Division of
Acquired Immunodeficiency Syndrome of the National Institute
of Allergy and Infectious Diseases (http://rcc.tech-res.com/
safetyandpharmacovigilance). Immunogenicity data was analyzed
and reported on all subjects who provided a sample at the time
point being assessed. Two subjects were excluded from the
immunogenicity analyses; one subject who was randomized to
receive placebo inadvertently was administered vaccine product
(50 mg of rPA with PBS) at the second inoculation and thus was
included in safety analysis, but not immunogenicity analysis. One
subject, randomized to the 100 mg rPA with PBS arm, had prior
undisclosed anthrax vaccine exposure as determined by detectable
levels of anti-rPA antibodies prior to injection of vaccine. This
volunteer denied anthrax vaccine exposure at entry and after
unblinding reported never being aware of receiving an anthrax
vaccine. This subject was also included in safety analysis, but
excluded from the immunogenicity analysis. The samples and data
were collected in Rockville MD USA at the Rockville Vaccine
Assessment Clinic (RVAC).
Trial Design
Subjects were enrolled into four sequential, escalating dosage
groups (5, 25, 50 or 100 mg of rPA) formulated in phosphate
buffered saline (PBS) or AlhydrogelH adjuvant resulting in 8
dosage/formulation groups as well as a placebo group (Figure 1).
The volunteers enrolled in the initial, open-label, phase of the trial
received vaccine containing the lowest antigen concentration
(5 mg) under study. Within the subsequent double-blind, placebo-
controlled portion of the study (25, 50 or 100 mg doses of rPA
formulated with PBS or AlhydrogelH), 10–11 volunteers were
randomized at each antigen dosage level to receive placebo (PBS
alone) or active agent (rPA) at one of the two formulations in a 1:4
ratio. Each vaccine or placebo was administered as two
intramuscular injections in the left deltoid four weeks apart. Safety
assessment included a diary of local reactions such as pain,
tenderness, or warmth and systemic reactions such as fatigue,
headache, or diarrhea for one week post-immunization which was
used as memory aid to identify solicited adverse events (post-
injection reactions, PIRs). The PIRs were recorded separate from
other adverse events (AEs) unless a PIR persisted beyond one week
post-injection. Also, at each of the 13 clinic scheduled visits,
samples were collected for hematology, serum chemistry, urinalysis
and immunogenicity.
Vaccine
The rPA component of the vaccine formulations tested in the
study was produced in E. coli by Cambrex BioScience Inc, now
Lonza Biologics Inc. (Hopkinton, MA). The bulk rPA was
formulated (25 mM Sodium Phosphate, 150 mM Sodium Chlo-
ride, pH 8.0) and vialed at Walter Reed Army Institute of
Research (WRAIR) Pilot BioProduction Facility, (Forest Glen,
MD). In addition, empty vials and vials containing diluent used to
prepare vaccine formulations were processed at the same facility.
AlhydrogelH is an aluminum hydroxide preparation manufactured
under cGMP by HCI BioSector (Frederikssund, Denmark). For
vaccine formulations containing adjuvant, rPA was adsorbed to
1.3% AlhydrogelH (w/v) resulting in formulations containing
704 mg of elemental aluminum per dose.
ELISA
The validated ELISA was performed with a modified version of
the protocol generously provided by Conrad Quinn and reported
previously [15]. Immulon 2 microtiter plates (Fisher Scientific,
Pittsburgh, PA) were coated with rPA (2 mg/ml) (List Biological
Laboratories Inc., Campbell, CA) in phosphate-buffered saline
[PBS, (Quality Biological, Gaithersburg, MD), pH 7.4] overnight
at 4uC. After washing the plates three times, reference standard
(Anti-AVA sera AVR801, kindly provided by Conrad Quinn,
CDC, Atlanta, GA), serum samples and controls were diluted in
serum diluent (5% skim milk in PBS with 0.1% Tween-20, pH 7.4)
and incubated in antigen-coated wells for one hour at 37uC. Plates
were then washed three times with wash buffer and incubated with
horseradish peroxidase (HRPO)-conjugated mouse anti-human
IgG (affinity purified, gamma chain specific monoclonal antibody,
clone HP6043 (Hybridoma Reagent Laboratory, Baldwin, MD)
(diluted 1:16,000 in serum diluent). After an hour incubation at
37uC, plates were washed three times, after which substrate
(ABTS; Kirkgaard & Perry, Gaithersburg, MD) was added and
plates were incubated for 30 minutes at 37uC. The reactions were
stopped and optical densities were read using a Molecular Devices
Vmax microplate reader with Softmax Pro software (Molecular
devices, Sunnyvale, CA). The endpoint titers were calculated using
software (ELISA for Windows) kindly provided by Conrad Quinn,
CDC Atlanta, GA [16]. For all calculations, values that were
below the lower limit of detection were given an arbitrary value of
‘‘1’’ and those below the limit of quantitation were given an
arbitrary value of ‘‘5’’.
Toxin neutralization assay (TNA)
The validated TNA was performed using a modified version of
the protocol provided by Conrad Quinn, CDC Atlanta, GA [16].
Briefly, J774A.1 cells (mouse macrophage/monocyte cells –
ATCC TIB-67) were used as targets for toxicity mediated by
rPA and recombinant lethal factor (rLF). A working solution of
anthrax toxin with a final concentration of rPA and rLF (List
Biological Laboratories Inc., Campbell, CA) at 0.1 mg/ml and
0.08 mg/ml, respectively was used in the assay. Sample sera were
diluted with a six-point 2-fold dilution scheme. Anti-AVA sera
pool AVR801 was used as a positive control and standard curve.
Normal human serum (NHS, Sigma, MO) was used as a negative
control. The working solution of toxin was added to plates that
contained serially diluted sample serum and after a 30 min
incubation, the toxin/sera was added to J77A.1 cells and
incubated for four hrs at 37uC. Cell viability was assessed by
adding 25 ml of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide] and incubating for an additional two hrs at
37uC. Prior to addition of 100 ml Solubilization Buffer [50% N, N-
Dimethylformamide (DMF) (Sigma, St. Louis, MO) with 20%
SDS (Sigma, St. Louis, MO), pH 4.7], which allows for
visualization of MTT color changes, media was removed from
plates by gently inverting and tapping the plates onto a paper
towel. Plates were read using a Molecular Devices Vmax
microplate reader with Softmax Pro software. The ED50 for
antibody-mediated protection from killing was calculated using the
‘‘c’’ parameter (or the mid-point) from the serum sample ODs
plotted in a 4-parameter curve from the Softmax Pro software. For
all calculations, values that were below the lower limit of detection
were given an arbitrary value of ‘‘1’’ and those below the limit of
quantitation were given an arbitrary value of ‘‘10’’.
Lymphocyte proliferation assay (LPA)
The LPA was modified from previously published assays [17].
Briefly, whole blood was collected in acid citrate dextrose (ACD)
citrate tubes and PBMC were separated by ficoll-hypaque density
centrifugation. Five million PBMC were set-aside for LPA and the
remaining PBMC were cryopreserved and stored in liquid
nitrogen. Triplicate wells of 100,000 fresh PBMC were incubated
Phase I Anthrax Vaccine Study
PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e13849in 96-well U-bottom plates with the following antigens or
mitogens: 1, 5 or 10 mg/ml of rPA (List Biological Laboratories
Inc., Campbell, CA), 2.5 or 5 mg/ml of tetanus toxin (List
Biological Laboratories Inc., Campbell, CA). In separate plates
100,000 fresh PBMC were stimulated with 2 mg/ml phytohaem-
agglutinin, 1.25 mg/ml pokeweed mitogen and 20 mg/ml con-
cavalinA. After three and six days of incubation at 37uC
respectively for the mitogens and antigens, cells were pulsed with
one mCi/well of [3H]-thymidine for six hr. Radioactivity
incorporated into dividing cells was assessed by measuring counts
per minute (cpm) in a Wallac Micobeta (Perkin Elmer, Shelton,
CT) scintillation counter. The data is expressed as a lymphocyte
stimulation index [LSI = (mean cpm of stimulated cells)/(mean
cpm of unstimulated cells)] to define antigen specificity. Samples
were designated as positive if the LSI was greater than or equal to
5. Assays were considered invalid if there was documentation of
technical failure due to lack of tritium incorporation, high
background cpm, not enough cells to complete the assay or lack
of response to the mitogens.
Ethics
The study was approved by independent institutional review
boards both at the Walter Reed Army Institute of Research and
the Human Subjects Review Board of the US Army Medical
Research and Materiel Command. Each participant gave written
informed consent and completed an exam of understanding prior
to engaging in any study-related procedure.
Statistical methods
Safety assessments for all volunteers were analyzed for all time
points using Fisher’s exact test. Immunogenicity data were
analyzed using Wilcoxon rank-sum and Kruskal-Wallis tests.
Correlation between ELISA and TNA results were assessed by
calculating the linear regression and applying the Spearman
correlation test. Prism 5 for Mac OS X (Graphpad, La Jolla, CA)
was used for all statistical calculations.
Results
This phase I trial was designed to examine the safety and
immunogenicity of rPA formulated with either in phosphate
buffered saline (PBS) or AlhydrogelH. The median age of enrolled
study subjects was 28 years; 51% were female. Of the 73
participants enrolled in the study, 60 (82.2%) completed all
vaccinations and follow-up visits, providing samples for immuno-
genicity assessment (Figure 1).
Safety and adverse events
Common local and systemic adverse events associated with
vaccines were solicited by clinic staff with the aid of diary cards
filled out by the volunteer and referred to as ‘‘post-injection
reactions’’ or PIRs. PIRs were defined as adverse events (AEs) that
occurred within the first 6 days after vaccination, which, due to the
close temporal (and as applicable, spatial) relation to injection,
were regarded as probably or definitely related to inoculation as
determined by the principal investigator. If any PIR had a
duration that lasted beyond 6 days post vaccination, it was
recorded as both a PIR and an AE. All local PIRs were of mild
severity. Overall, 47/62 (76%) rPA recipients had a local PIR, the
majority of these subjects (40/47: 85%) experienced tenderness
(Figure 2). Warmth, pain and erythema were the next most
common PIRs observed. The most common local PIRs for
placebo recipients were tenderness (5/11, 45%) and warmth (2/
11, 18%) (Figure 2). The rate of local reactions for placebo
recipients (7/11: 64%) was not statistically different from those of
vaccine recipients (Fisher’s exact test, p=0.46). Overall, 28/62
(45%) of rPA recipients and 4/11 (36%) of placebo recipients
experienced a systemic PIR again with no statistical difference
between rPA and placebo recipients (Fisher’s exact test, p=0.75).
The most common systemic PIR was fatigue for both vaccine (13/
62, 20%) and placebo (3/11, 27%) recipients (Figure 2). All
systemic PIRs observed were mild except for a single febrile
episode graded as ‘‘moderate’’ (temperature measured as 101.7uC
2 days after the first injection) in a volunteer who received 50 mgo f
rPA without adjuvant. There appeared to be no relationship to
dose or adjuvant observed with regard to systemic reactions,
however the groups receiving 50 mg of rPA with adjuvant, as well
as those receiving 100 mg of rPA with or without adjuvant
appeared to have the most local reactions (Figure 2). After
receiving the first injection, 39% of rPA recipients had a local PIR
and 40% had a systemic PIR. The percentage of rPA recipients
with a local PIR went up to 58% after the second injection, while
the percentage of reported systemic PIRs went down to 15%. Of
the placebo recipients, 55% and 27% reported local and systemic
PIRs, respectively, after the first injection. After the second
injection, 27% and 9% reported local and systemic PIRs,
respectively.
There were a total of 54 out of 62 subjects who reported AEs
that occurred 6 days after receipt of rPA (or PIRs that continued in
duration past 6 days), however, only 8 were judged to be possibly,
probably or definitely related to the vaccine and all were of mild
severity (Figure 3). Of these, 3 were mild fatigue and 4 were mild,
prolonged injection site reactions, the longest lasting 10 days. The
remaining related AE was a case of hypoesthesia in the forearm
opposite the administration arm of an individual in the 100 mg
rPA/adjuvant group. Only one serious adverse event occurred, an
idiopathic cardiomyopathy arising 5 months after the second
vaccination with 5 mg of rPA formulated with alum, but was
judged to be unrelated to the vaccine. There were AEs in 10 of 11
placebo recipients, all being mild or moderate, none judged to be
related to the injection. Urine and blood collected for laboratory
analysis showed no difference in the frequency of abnormalities for
each analyte as a function of vaccine or dose. Of the lab
abnormalities, none were graded as an AE related to the vaccine.
The proportion of all lab abnormalities observed in vaccine and
placebo groups were similar with 49 lab abnormalities of 407
(12%) of placebo assessments compared to 254 abnormalities of
2183 lab assessments (11.6%) in the vaccine group. Further, there
was no difference in the proportion of lab abnormalities as a
function of dose group or adjuvant (data not shown).
Overall Immunogenicity
Among the participants receiving rPA, all produced binding
antibodyexceptforthree participantsatthe5 mg dose formulated in
PBS and one participant at the 25 mg dose formulated in PBS.
Considering all three assays for immunogenicity, there was only one
participant who received rPA (in the 25 mg PBS formulation group)
that did not respond to the immunogen. The toxin neutralization
assay (TNA) was able to detect responses in sera from all vaccinees,
except the previously mentioned participant. The lymphocyte
proliferation assays (LPA) response rate was lower compared to the
other two assays, especially at the higher concentrations of rPA
(50 mg and 100 mg). No rPA specific immune responses were
detected by TNA or LPA in placebo recipients (data not shown);
however, detectable, but unquantifiable, levels of anti-rPA specific
antibodieswerefoundintwoparticipantswhoreceivedplacebo.For
one of these participants, this activity was found in a single sample
obtained prior to initiation of study injections, while for the other
Phase I Anthrax Vaccine Study
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low level (15 mg/ml of anti-rPA antibodies) transiently. However,
this sample was approximately 30 days post placebo injection (data
notshown),indicatingthatthesemeasurementsweremostlikelydue
to non-specific binding.
Humoral Immunogenicity
Anti-rPA specific antibodies responses among rPA recipients are
shown in Figure 4. The peak geometric mean concentration
(GMC) of anti-rPA antibodies was observed 2 weeks after the
second vaccination and diminished over time to low, but
detectable, levels by the final study visit. Antibody levels were
quite low after the initial injection, while the second vaccination
elicited a much stronger immune response. For all rPA doses,
inclusion of adjuvant with the rPA stimulated GMCs equal to, and
in most cases higher than GMC produced following receipt of rPA
alone at 2 weeks post-second immunization. This was most
pronounced in the 5 mg and 25 mg groups (Figures 4 and 5).
Within the 5 mg dosage level group, the difference between
Figure 2. Post-injection reactions (PIRs). The X axis displays the dosage groups along with all of the placebos, who were combined into one
group. The Y axis displays the PIRs that were assessed in the study. The data displayed in the matrix represents the number of individuals who
reported a given PIR and the size of the circle is proportional to the reported number. The top half of the graph consists of systemic PIRs while the
bottom half of the graph consists of local PIRs.
doi:10.1371/journal.pone.0013849.g002
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significance (Wilcoxon rank-sum p=0.06) and achieved signifi-
cance for the 25 mg dose group (Wilcoxon rank-sum p=0.03). The
50 mg and 100 mg groups had similar GMCs 2 weeks after the
second vaccination independent of the presence of adjuvant
(Wilcoxon rank-sum p=0.69 and 0.31 respectively). The relative
difference between the two formulations was maintained for all
groups through the final visit. Participants who received 5 mg rPA
(both formulations) or 25 mg rPA with PBS no longer had
quantifiable levels of anti-rPA antibodies at the final visit. Of the
24 volunteers within the groups who received the lower two doses
of rPA, only 3 (12.5%) had both detectable and quantifiable
concentrations of anti-rPA antibodies, all of whom were in the
AlhydrogelH-formulated 25 mg rPA group. Of the volunteers
within the groups who received the higher two doses of rPA
formulated with PBS, 8 out of 14 (57%) had both detectable and
quantifiable concentrations of anti-rPA antibodies at the final visit
as compared to 9 out of 12 (75%) of the dose-matched group who
received rPA formulated with adjuvant (data not shown). Overall,
the volunteers who received either the 50 mg or 100 mg dose of
rPA, regardless of formulation, had significantly higher GMCs of
anti-rPA specific antibodies at the final visit than those who
Figure 3. Adverse events (AEs). The number of AEs was tallied for each dosage group, as well as all of the placebos, who were combined into one
group. The empty bars represent AEs that were determined to be not related to the vaccine. The filled bars represent AEs that were determined to be
related to the vaccine. The dotted line indicates the total number of volunteers in each group. All AEs that were determined to be related to the
vaccine were mild in severity.
doi:10.1371/journal.pone.0013849.g003
Figure 4. Geometric mean concentration of anti-rPA antibodies over time. The concentration of anti-rPA antibodies was assessed by ELISA
at weeks 0, 2, 6, 10, 26, and 52 over the course of the entire study. Arrows indicate when the two injections occurred.
doi:10.1371/journal.pone.0013849.g004
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Despite this significance, the range of GMCs of all eight groups
was quite low (1.3–12.7 mg/mL).
To further assess the influence of rPA antigen dose and adjuvant
inclusion on the elicitation of a humoral response, the concentra-
tions of anti-rPA binding antibody and neutralizing antibody
(TNA) effective dilution 50 (ED50) titers measured from partici-
pants 2 weeks after the second vaccination were plotted (Figure 5).
The anti-rPA antibody titers escalated between groups receiving
5 mgt o5 0mg of rPA, peaking in the group that received 50 mg;
this was irrespective of rPA formulation. The AlhydrogelH-
formulated rPA elicited higher anti-rPA antibody concentrations
than rPA without adjuvant for the lower immunogen concentra-
tion groups (5 mg and 25 mg), however, there was no discernable
difference between GMCs in the higher dosage groups (50 mg and
100 mg). A similar pattern was seen in the TNA. The geometric
mean titers (GMTs) of the ED50s were higher at 5 mg and 25 mgo f
rPA doses of rPA in the AlhydrogelH receiving groups than those
from the PBS groups (Figure 5). At 50 mg and 100 mg of rPA, the
GMTs were almost equivalent. Similar to the ELISA, peak GMTs
were observed at 50 mg.
To assess if the results obtained from the ELISA and the TNA
correlated, the concentration of anti-rPA antibodies was plotted (Y
axis) against the neutralizing ED50 (X axis) for each participant
(Figure 6). The two assays were highly correlated, with a linear
regression R
2 of 0.86. Using the Spearman test for correlation, the
R-value was 0.93 with a p value of ,0.0001.
Cellular Immunogenicity
Cellular immune responses to rPA were assessed by incubating
peripheral blood mononuclear cells (PBMC) with 10, 5 (data not
shown) and 1 mg/ml of rPA; data are expressed as a lymphocyte
stimulation index (LSI) where an LSI $5 is considered a positive
response (closed circles). Responses to control mitogens were
positive for all volunteers shown and tetanus responses were
consistent across visits for each volunteer in the LPA (data not
shown). Post vaccination, the median LSI to rPA ranged from 4.5
to 28.5. Two weeks after the second injection, the groups
immunized with lower concentrations of rPA (5 mg/ml and
25 mg/ml) in both formulations showed a robust response to
rPA with each group only having one non-responder (Figure 7). In
the groups that received either 50 mg or 100 mg of rPA with
AlhydrogelH, there were fewer rPA responders. While the same
phenomenon was seen in the 50 mg PBS group, the 100 mg PBS
group only had one non-responder. Only 2 of the 62 participants
showed a proliferative response to rPA prior to vaccination with
LSI of 6 and 8 respectively (data not shown).
Discussion
This study assessed the safety of E. coli derived rPA in a phase I
trial in humans. At the dosages and formulations tested, the
vaccine was found to be safe and well tolerated. All PIRs were of
mild severity, aside from one (graded moderate) febrile episode.
The most common PIR reported as tenderness of the injection site
(Figure 2). Among 54 rPA recipients reporting AEs, 8 were judged Figure 5. Vaccine induced humoral immunogenicity. (A) The
geometric mean concentrations (GMC) of the anti-rPA antibodies and
(B) the geometric mean reciprocal 50% titers (GMT) for the TNA were
calculated for each group (horizontal bars) at study visit 8 (2 weeks post
second vaccination). The scattergram of the individual responses
displays participants who received rPA formulated without AlhydrogelH
adjuvant (PBS) in blue and participants whom received rPA formulated
with AlhydrogelH in red.
doi:10.1371/journal.pone.0013849.g005
Figure 6. Correlation between the concentration of anti-rPA
binding antibodies and the ED50 for the individual samples.
The plot depicts the relationship between the level of anti-rPA antibody
binding and the neutralization ED50 in the TNA. A linear regression (grey
line) indicates a strong correlation between the two parameters
(R
2=0.86). All samples from rPA recipients are included in the linear
regression calculation, however, only the data that were above the limit
of quantitation for both assays are displayed.
doi:10.1371/journal.pone.0013849.g006
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general disorders and administration site conditions (Figure 3). In
contrast to a previous report with a similar rPA vaccine [13], we
did not observe a difference in reactogenicity between men and
women (data not shown). However, the small number of study
subjects in this trial precludes a robust comparison on this point.
Vaccine formulations of rPA with and without AlhydrogelH
were immunogenic. The humoral responses, as measured by
ELISA for binding antibodies and TNA for neutralizing
antibodies, follow similar patterns (Figure 5) and the values
correlate well (Figure 6), which is in line with prior observations
following natural infection and vaccination with Biothax
TM
[13,16,18]. We show here, as have others [14] that formulation
with AlhydrogelH tended to enhance antibody responses, especially
at 5 mg and the 25 mg dosage levels where, at 2 weeks post-second
vaccination (near the presumed peak of immunogenicity), the
GMCs of anti-rPA antibodies were nearly a log higher in the
groups receiving AlhydrogelH-formulated rPA than those in
groups receiving PBS-formulated rPA (Figure 4). At later post-
vaccination time points, the concentration of rPA antigen appears
to influence the levels of anti-rPA antibodies more than the
presence of adjuvant (Figure 5), however, due to the narrow
range of GMCs for all eight groups it is unknown if there is
biological relevance in terms of potential protection between these
values.
The relatively rapid decrease in anti-rPA antibody titers after
receipt of the second injection that we observed in this study has
been recognized previously [18]. In the current Biothrax
TM
vaccination schedule, injections are given at 0, 4 weeks and 6, 12,
and 18 months with annual boosts recommended to maintain
high levels of anti-PA antibodies [8]. In humans, the previous
schedule for Biothrax
TM included three injections 2 weeks apart
with 3 more injections occurring at 6, 12, and 18 months [19].
The fourth injection was shown to be critical for maintenance of
higher levels of antibodies for prolonged periods of time [18].
However after only two Biothrax
TM vaccinations, protection was
still achieved with challenges two years post-vaccination in rhesus
macaques [3,20] despite relatively low levels of anti-PA
antibodies present in the monkeys at the time. While efforts
have been made to determine what levels of antibody are
r e q u i r e df o rp r o t e c t i o ni nb o t hr a b b i t s[ 2 1 , 2 2 ]a n dg u i n e ap i g s
[23], these values may or may not translate into protection for
humans. A recent study using a monoclonal antibody (mAb)
against PA in rabbits and monkeys found that a concentration of
40 mg/kg lead to 100% protection in rabbits and 90% protection
in cynomolgus monkeys. While the dosage groups in our study
did not reach this level of antibody, protection in the setting of a
vaccine involves not only neutralizing antibodies present at the
time of exposure, but also the time involved with stimulating the
memory immune response. Interestingly, humans vaccinated
with the United Kingdom’s licensed human anthrax vaccine had
measurable T cell immune responses 10–15 years after
vaccination without boosts [24].
To our knowledge, this is the third published study that
examines the safety and immunogenicity of a recombinant PA
vaccine. Some trends become evident by comparing the studies.
First, as has been noted [14], increased amounts of AlhydrogelH
within the rPA vaccine formulation enhances humoral immuno-
genicity. Formulation of 704 mg (used in this study) or 800 mg [14]
of elemental aluminum with 50 mg of rPA resulted in higher
GMCs of anti-rPA binding antibodies and higher GMTs of
neutralizing antibodies than formulation with 82.5 mg of Alhy-
drogelH [13] with rPA after two immunizations. To achieve similar
GMCs and GMTs using less AlhydrogelH, a third immunization is
required [13]. Second, when rPA is formulated with at least
704 mg of AlhydrogelH, doses of rPA above 50 mg unexpectedly
show a slight decrease in immunogenicity (Figure 5 and [14])
instead of an increase.
The cellular response to anthrax toxins has rarely been studied,
most likely because the role that anti-PA antibodies play in
protection has been so well documented [7]. However, the cellular
response is critical for the support of antibody production. Studies
of cell-mediated immune responses in individuals exposed to
anthrax spores from bio-terrorism attacks in the Capitol building
in 2001 demonstrated that the CD4+ immune response is potently
stimulated in a dose-dependent manner by anthrax spores [25].
The magnitude of cell-mediated responses elicited from rPA-based
vaccines in humans has yet to be reported. Here we have seen that
the groups of participants who received the higher doses of
adjuvanted rPA had fewer responses than those who received the
lower doses of adjuvanted rPA (Figure 7). This trend does not
correlate with the ELISA or TNA data, where the higher doses of
rPA resulted in higher humoral responses. Additionally, results
Figure 7. Vaccine induced lymphocyte proliferation. The LPA
was performed on fresh cells obtained the day of the assay from
participants at study visit 8 (2 weeks post second vaccination)
incubated with 1 mg/ml of rPA. The resultant lymphocyte stimulation
index (LSI) is plotted for all rPA-receiving participants. The individual
data points are overlaid on box and whiskers plots, which show the
median and percentiles for the data within each group. (A) Individuals
whom received rPA formulated without AlhydrogelH adjuvant (PBS). (B)
Individuals whom received rPA formulated with AlhydrogelH. Negative
values (LSI #5) are denoted by open circles.
doi:10.1371/journal.pone.0013849.g007
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conflicting. The 50 mg dose has fewer responders, appearing to
follow the trend observed in the higher doses of the AlhydrogelH-
formulated rPA. The 100 mg PBS-formulated dose, however,
showed only one non-responder, similar to the lower doses (both
formulations). The assessment of T cell stimulation through LPA
provides indirect evidence of T cell help induced by the vaccine
regimen. However, the observed T cell response did not directly
correlate with the humoral response. Additionally, these data
conflict with the data generated from spore exposure in humans
[25]. It is probable that spores activate the T-helper cell response
more potently than does rPA alone. One caveat is that the sample
size for each group is quite small (n=5–8, depending on the
group), thus the current trends may be different than trends that
would be observed in larger datasets. Further experiments are
required to explore this issue.
The E. coli derived rPA product evaluated for the first time in
humans in this study was safe, well-tolerated and produced
humoral immune responses comparable to those observed in
previous human trials of other recombinant PA vaccines. Based on
the safety and immunogenicity data described here, 50 mg of rPA
formulated with AlhydrogelH would provide the best immune
response while minimizing the amount of antigen administered.
Further study of this product with a late boost or novel adjuvants
may enhance durability and peak immune response.
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